Padeliporfin potassium is under clinical development by ImPact Biotech and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase I drugs for Pancreatic Ductal Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Padeliporfin potassium LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Padeliporfin potassium overview
Padeliporfin dipotassium (Tookad) is a vascular-acting photosensitizer consisting of a water-soluble, palladium-substituted bacteriochlorophyll derivative which acts as an antineoplastic agent. It is formulated as lyophilized powder for solution for intravenous route of administration. It is indicated for treatment of treatment for other solid tumors. Photodynamic Therapy (PDT) is a non conventional light therapy for treatment of cancer. It uses photosensitive drugs, that are triggered by light from a specific wavelength usually red or infrared on the light spectrum chart. Vascular targeted photodynamic therapy (VTP) with padeliporfin allows tumor-site specific cytotoxicity while.
It is under development for the treatment of pancreatic ductal adenocarcinoma, esophageal cancer, urothelial cell cancer, peripheral primary non-small cell lung cancer and myopia. It was also under development for cholangiocarcinoma, choroidal neovascularization, endobronchial cancer, renal cancer, prostate cancer and non-small cell lung cancer.
ImPact Biotech overview
ImPact Biotech is focused on the development of Padeliporfin VTP Therapy, a targeted treatment for tumor ablation in upper tract urothelial carcinoma, and lung and pancreatic cancer. The company is headquartered in Ness Ziona, Israel.
For a complete picture of Padeliporfin potassium’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
